Mechanisms of Antipsychotic Action: From the Researcher Bench to the Patient Bedside 2.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 4489
Special Issue Editor
Interests: neurotransmitter
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Schizophrenia is among the most debilitating causes of morbidity worldwide, with a progressively worsening course. The WHO stated that schizophrenia should be treated by integrated therapeutic strategies, including pharmacological and non-pharmacological interventions, both considered mandatory to cure these patients efficaciously. The mainstay of pharmacological treatment of schizophrenia is the class of Antipsychotic agents, which comprises several chemically unrelated compounds. However, all antipsychotics (with the possible exception of clozapine) share a variable degree of action as dopamine D2 receptor blockers. Despite this common mechanism of action, antipsychotics exert molecular actions on multiple dopaminergic and non-dopaminergic receptors. The relevance to the therapeutic efficacy of these actions, as well as their molecular consequences, are largely unknown. Also, the molecular effects triggered by antipsychotics after their interaction with target receptors have been only limitedly characterized.
The lack of in-depth data on antipsychotic molecular action is a major cause of relevant clinical challenges since currently available antipsychotics suffer from several limitations in the treatment of schizophrenia. According to some estimations, approximately 30% of all schizophrenia patients have positive symptoms that are unresponsive or only minimally responsive to antipsychotics. The so-called negative symptoms, which include several distinct pathological phenotypes, as well as cognitive dysfunctions in schizophrenia patients are not ameliorated by current antipsychotics. Also, it has been suggested that antipsychotics may cause iatrogenic worsening and/or occurrence of negative or cognitive symptoms. Unfortunately, these symptoms are those maximally associated with long-term disability in schizophrenia patients and pharmacological therapeutic strategies addressing them are among the most relevant unmet need of schizophrenia clinics. As a further consideration, antipsychotics are burdened from multiple side effects, that in part stem from their therapeutic mechanism of action but, in many other cases, derives from the action on receptor targets that are not strictly necessary for their efficacy against psychotic symptoms.
All these considerations indicate the urge to gain more insights into the molecular mechanism of actions of currently available antipsychotics and to unravel other mechanisms of action, even including the possibility of sharp paradigmatic changes, e.g., using small molecules; gene therapy; or acting on post-receptor or non-receptor neuronal sites.
This special issue is supervised by Dr. Felice Iasevoli and assisted by our Topical Advisory Panel Member Dr. Annarita Barone (University School of Naples "Federico II). The Special Issue, “Mechanisms of Antipsychotic Action: From the Researcher Bench to the Patient Bedside 2.0” of the International Journal of Molecular Sciences will include a selection of research papers and reviews about various aspects of the molecular and cellular biology of antipsychotics. In addition, studies on molecules able to modulate various aspects of synaptic signaling, and their possible use in the treatment of psychotic diseases will also be considered.
Dr. Felice Iasevoli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- schizophrenia
- glutamate
- dopamine
- gene expression
- synapse
- post-synaptic density
- second-messenger
- psychosis
- synaptic plasticity
